The democratization of gene therapy

New manufacturing plant

01Viralgen Commercial

EMA and FDA inspected

Viralgen Commercial is the next phase of our ambitious project started in 2017.

Once it is done, it will be the largest plant in the world in the manufacture of Adeno-associated vectors - known as AAVs - for use in the treatment of diseases.

Large-scale manufacturing will allow the supply of the product beyond clinical trials. In this way, Viralgen Commercial democratizes access to gene therapy, both due to the volume and speed of production by increasing throughput and yield, and lowering costs of manufacturing.

It represents a historic advance for patients, science and medicine.

It places the organization, the Basque Country and Spain at the forefront at the forefront of the sector worldwide.

Viralgen Commercial illustrates the power of scientific innovation when it focuses on human impact. For patients, it symbolizes advancement of healing therapies and hope for a cure.

50M €
Total
Investment
+200
New
Jobs
14k m²
Footprint
15x
Capacity
Increase
3
Buildings
3x2000 L
GMP SUITES
PER BUILDING
12k m²
Each Building

02The new manufacturing plant

Viralgen Commercial is the next phase of our ambitious project started in 2017.

Once it is done, it will be the largest plant in the world in the manufacture of Adeno-associated vectors - known as AAVs - for use in the treatment of diseases.

Large-scale manufacturing will allow the supply of the product beyond clinical trials. In this way, Viralgen Commercial democratizes access to gene therapy, both due to the volume and speed of production by increasing throughput and yield, and lowering costs of manufacturing.

03Project progress

Image alt

04Look at the works